Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Vaccine in Adults 60 Years of Age and Older
NCT07819097Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 2
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Sep 2026; status: recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07819097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819097.